Drug-labels.com

Mar-Apremilast: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
10 mg / 20 mg / 30 mg, 30 mg
Active ingredient:
ATC code:

Patient Medication Information: uses, side effects, how to take - Mar-Apremilast

ABOUT THIS MEDICATION

What the medication is used for:

MAR-APREMILAST is used in adults to treat:

  • moderate to severe plaque psoriasis.
  • psoriatic arthritis. For these patients, MAR-APREMILAST will be given alone or in combination with methotrexate. It will be given if you cannot use another type of medicine called ‘Disease-Modifying Antirheumatic Drugs’ (DMARDs) or if you have tried one of these medicines and it did not work.
  • oral ulcers associated with Behçet’s disease.

MAR-APREMILAST is not approved for use in combination with any other medicines taken by mouth used to treat psoriasis, biological therapies (such as TNF antagonists and anti-IL-12/23 p40 antibodies) or with phototherapy (light therapy using UV light).

What it does:

MAR-APREMILAST belongs to a class of drugs called phosphodiesterase 4 (PDE4) inhibitors. It contains the active ingredient apremilast which works by reducing the activity of PDE4. This results in less inflammation in the skin and joints.

When it should not be used:

Do not take MAR-APREMILAST if you:

  • are allergic to apremilast or to any non-medicinal ingredient in the formulation.
  • have one of the following rare hereditary diseases:

    • Galactose intolerance
    • Lapp lactase deficiency
    • Glucose-galactose malabsorption

because lactose is a non-medicinal ingredient in MAR-APREMILAST.

  • are breastfeeding. It is not known if MAR-APREMILAST passes into your breast milk.

    • MAR-APREMILAST should not be used if you are breastfeeding.
    • are younger than 18 years old.
    • are pregnant or intend to become pregnant. It is not known if MAR-APREMILAST will harm your unborn baby. If you take MAR-APREMILAST while you are pregnant, talk to your doctor about how you can be included in the MAR-APREMILAST Enhanced Surveillance Program for Adverse Pregnancy Outcomes.

What the medicinal ingredient is:

apremilast

What the nonmedicinal ingredients are:

Anhydrous Lactose, croscarmellose sodium, ferrosoferric oxide/black iron oxide (for 30mg), hypromellose, iron oxide yellow (for 20 mg and 30 mg), lactose monohydrate, microcrystalline cellulose, magnesium stearate, HPMC/ titanium dioxide, triacetin, iron oxide red

What dosage forms it comes in:

Tablets: 10 mg, 20 mg and 30 mg.

WARNINGS AND PRECAUTIONS

BEFORE you use MAR-APREMILAST talk to your doctor or pharmacist if you:

  • have kidney problems.
  • have a history of the heart condition, tachyarrhythmia (fast heartbeat or heart palpitations).
  • have heart disease or congestive heart failure.
  • have tuberculosis or a viral infection such as viral hepatitis, herpes infection or shingles.
  • are using immunosuppressive drugs (such as cyclosporine).
  • have a history of depression and/or suicidal thoughts or behaviours.
  • have low blood pressure
  • have any other medical conditions.
  • 65 years of age or older.

MAR-APREMILAST can cause weight loss. Your doctor will need to regularly monitor your weight.

INTERACTIONS WITH THIS MEDICATION

As with most medicines, interactions with other drugs are possible. Tell your doctor or pharmacist about all

IMPORTANT: PLEASE READ

the medicines you take, including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines.

The following may interact with MAR-APREMILAST:

  • Rifampin, used to treat tuberculosis.
  • Medicines used to control seizures such as phenobarbital, carbamazepine and phenytoin.
  • Medicines that suppress your immune system such as cyclosporine and tacrolimus.
  • Methotrexate to treat your psoriasis
  • Biological therapies, such as TNF antagonists and anti-IL-12/23 p40 antibodies.
  • The botanical medicine St. John’s Wort.

PROPER USE OF THIS MEDICATION

Take MAR-APREMILAST exactly as your healthcare provider tells you to take it. MAR-APREMILAST should be taken by mouth and swallowed whole, with or without food. The tablets should not be crushed, split, or chewed.

Usual adult dose:

The recommended dose is 30 mg twice a day. When you first start taking MAR-APREMILAST, the dose needs to be increased gradually; therefore, you must follow the instructions below.

Dose titration schedule:

Day 1Day 2Day 3
AM
AMPM
AMPM
10 mg
10 mg10 mg
10 mg20 mg
Day 4Day 5Day 6
AM
PM
AMPM
AMPM
20 mg
20 mg
20 mg30 mg
30 mg30 mg

Overdose:

Missed Dose:

If you miss a dose of MAR-APREMILAST, take it as soon as you remember. If it is close to the time for your next dose, just skip the missed dose. Take the next dose at your regular time. Do not double dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, MAR-APREMILAST can have side effects. If any of these side effects affect you severely, tell your doctor, nurse or pharmacist:

  • diarrhea
  • nausea
  • vomiting
  • headache
  • upper respiratory tract infection (e.g. common cold)
  • flu (body aches and pains, tiredness, fever)
  • decreased appetite
  • abdominal discomfort, indigestion
  • fatigue, trouble sleeping
  • back pain
  • joint discomfort or pain
  • dizziness.

If you think you or a person you are caring for, have taken too much MAR-APREMILAST, contact healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

IMPORTANT: PLEASE READ

This is not a complete list of side effects. For any unexpected effects while taking MAR-APREMILAST, contact your doctor or pharmacist.

HOW TO STORE IT

Store MAR-APREMILAST at 15°C to 30°C.

Keep MAR-APREMILAST tablets and all medicines out of the reach and sight of children.

MORE INFOR M ATION

If you want more information about MAR-APREMILAST:

  • Talk to your healthcare professional
  • Find the full product monograph that is prepared for healthcare professionals and includes this Consumer Information by visiting the Health Canada website: (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); Marcan Pharmaceuticals Inc.’s website www.marcanpharma.com, or by calling 1-855-627-2261.

Marcan Pharmaceuticals Inc.

2 Gurdwara Road, Suite #112

Ottawa, ON, K2E 1A2

Last Prepared: June 22, 2022

SERIOUS SIDE EFFECTSAND WHAT TO DO ABOUT THEM

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Symptom / effectTalk to your healthcare professionalStop taking drug and get immediate medical help
Only if severeIn all cases
COMMON
Migraine√
Depression√
Weight loss√
UNCOMMON
Palpitations: Fast and/or irregular heartbeat√
Allergic reaction: Rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing√
Infection of the lungs: Shortness of breath, difficult and painful breathing, cough, wheezing and fever√
Gastrointestinal hemorrhage (bleeding in the digestive tract): black, tarry stool; blood coming from the rectum, blood in vomit√
Severe diarrhea: Loose, watery stool√
Severe nausea: Feeling the need to throw-up√
Severe vomiting: Throwing up√

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02528347

Revision date stated in the text: June 22, 2022

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Mar-Apremilast

Rx or OTC
Prescription (Rx)?
DIN 02528347, 02528355
Schedule(s) PRESCRIPTION
Active ingredient(s) Apremilast
Dosage form(s) Tablet
Route(s) of administration Oral
Drug class (WHO ATC)
  1. L Antineoplastic and immunomodulating agents
    1. L04 Immunosuppressants
      1. L04A Immunosuppressants
        1. L04AA Selective immunosuppressants
          1. L04AA32 Apremilast
Company MARCAN PHARMACEUTICALS INC
Current status Approved
Current status date November 14, 2022
Strengths and forms
DIN Strength Dosage form(s) Current status
02528347 10 MG / 20 MG / 30 MG Tablet Approved November 14, 2022
02528355 30 MG Tablet Approved November 14, 2022

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.